Cargando…
A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea
BACKGROUND: AGI004 is a controlled-release transdermal patch preparation of mecamylamine. We conducted a randomised placebo-controlled phase II study of two dose levels of AGI004 in chemotherapy-induced diarrhoea (CID). METHODS: Adult patients receiving chemotherapy who had experienced diarrhoea (NC...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619064/ https://www.ncbi.nlm.nih.gov/pubmed/23462724 http://dx.doi.org/10.1038/bjc.2013.35 |
_version_ | 1782265458008784896 |
---|---|
author | Coyle, V M Lungulescu, D Toganel, C Niculescu, A Pop, S Ciuleanu, T Cebotaru, C Devane, J Martin, M Wilson, R H |
author_facet | Coyle, V M Lungulescu, D Toganel, C Niculescu, A Pop, S Ciuleanu, T Cebotaru, C Devane, J Martin, M Wilson, R H |
author_sort | Coyle, V M |
collection | PubMed |
description | BACKGROUND: AGI004 is a controlled-release transdermal patch preparation of mecamylamine. We conducted a randomised placebo-controlled phase II study of two dose levels of AGI004 in chemotherapy-induced diarrhoea (CID). METHODS: Adult patients receiving chemotherapy who had experienced diarrhoea (NCI grade 1–2) during previous cycles of chemotherapy were eligible. In all, 64 patients were randomised to receive AGI004 4 mg then 8 mg per 24 h transdermal patch or placebo for two sequential cycles of chemotherapy. Patients' severity of diarrhoea was physician-assessed using NCI grade of diarrhoea and patient-assessed using information recorded in daily diaries of bowel movements. RESULTS: Overall AGI004 doubled the odds of a response to treatment on the first day of chemotherapy based on physician assessment of NCI grade of diarrhoea compared with placebo (odds ratio=2.0, 90% confidence interval: 0.9–4.5) and there was a trend to improved response rates for AGI004 for the full treatment cycle although these results were not statistically significant. There was also evidence of significantly improved response rates based on patient assessment of diarrhoea both overall (P=0.05) and at the 8-mg dose level (P=0.02) compared with placebo. CONCLUSION: AGI004 demonstrated effectiveness in reducing chemotherapy-associated diarrhoea, with results suggesting response across multiple measurements of diarrhoea. Treatment was well tolerated with no drug-related adverse events. Further evaluation of this agent in the management of CID is warranted. |
format | Online Article Text |
id | pubmed-3619064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-36190642014-03-19 A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea Coyle, V M Lungulescu, D Toganel, C Niculescu, A Pop, S Ciuleanu, T Cebotaru, C Devane, J Martin, M Wilson, R H Br J Cancer Clinical Study BACKGROUND: AGI004 is a controlled-release transdermal patch preparation of mecamylamine. We conducted a randomised placebo-controlled phase II study of two dose levels of AGI004 in chemotherapy-induced diarrhoea (CID). METHODS: Adult patients receiving chemotherapy who had experienced diarrhoea (NCI grade 1–2) during previous cycles of chemotherapy were eligible. In all, 64 patients were randomised to receive AGI004 4 mg then 8 mg per 24 h transdermal patch or placebo for two sequential cycles of chemotherapy. Patients' severity of diarrhoea was physician-assessed using NCI grade of diarrhoea and patient-assessed using information recorded in daily diaries of bowel movements. RESULTS: Overall AGI004 doubled the odds of a response to treatment on the first day of chemotherapy based on physician assessment of NCI grade of diarrhoea compared with placebo (odds ratio=2.0, 90% confidence interval: 0.9–4.5) and there was a trend to improved response rates for AGI004 for the full treatment cycle although these results were not statistically significant. There was also evidence of significantly improved response rates based on patient assessment of diarrhoea both overall (P=0.05) and at the 8-mg dose level (P=0.02) compared with placebo. CONCLUSION: AGI004 demonstrated effectiveness in reducing chemotherapy-associated diarrhoea, with results suggesting response across multiple measurements of diarrhoea. Treatment was well tolerated with no drug-related adverse events. Further evaluation of this agent in the management of CID is warranted. Nature Publishing Group 2013-03-19 2013-03-05 /pmc/articles/PMC3619064/ /pubmed/23462724 http://dx.doi.org/10.1038/bjc.2013.35 Text en Copyright © 2013 Cancer Research UK http://creativecommons.org/licenses/by-nc-sa/3.0/ From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/ |
spellingShingle | Clinical Study Coyle, V M Lungulescu, D Toganel, C Niculescu, A Pop, S Ciuleanu, T Cebotaru, C Devane, J Martin, M Wilson, R H A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea |
title | A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea |
title_full | A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea |
title_fullStr | A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea |
title_full_unstemmed | A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea |
title_short | A randomised double-blind placebo-controlled phase II study of AGI004 for control of chemotherapy-induced diarrhoea |
title_sort | randomised double-blind placebo-controlled phase ii study of agi004 for control of chemotherapy-induced diarrhoea |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3619064/ https://www.ncbi.nlm.nih.gov/pubmed/23462724 http://dx.doi.org/10.1038/bjc.2013.35 |
work_keys_str_mv | AT coylevm arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT lungulescud arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT toganelc arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT niculescua arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT pops arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT ciuleanut arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT cebotaruc arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT devanej arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT martinm arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT wilsonrh arandomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT coylevm randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT lungulescud randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT toganelc randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT niculescua randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT pops randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT ciuleanut randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT cebotaruc randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT devanej randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT martinm randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea AT wilsonrh randomiseddoubleblindplacebocontrolledphaseiistudyofagi004forcontrolofchemotherapyinduceddiarrhoea |